The presence of anti-centromere antibodies may predict progression of estimated pulmonary arterial systolic pressure in systemic sclerosis

Scandinavian Journal of Rheumatology

Volumn 37, Issue 4, 2008, Pages 278-283

  Kampolis, C ^a,b   Plastiras, S C ^a   Vlachoyiannopoulos, P G ^a,b   Moyssakis, I ^b   Tzelepis, G E ^a,b  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b LAIKO GENERAL HOSPITAL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

CENTROMERE ANTIBODY;

ADULT; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; ECHOCARDIOGRAPHY; FEMALE; FIBROSIS; FORCED EXPIRATORY VOLUME; HUMAN; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PRIORITY JOURNAL; PULMONARY ARTERY; RAYNAUD PHENOMENON; SKIN MANIFESTATION; SYSTEMIC SCLEROSIS; SYSTOLIC BLOOD PRESSURE; TIME;

ADULT; ANTIBODIES, ANTINUCLEAR; CENTROMERE; DISEASE PROGRESSION; ECHOCARDIOGRAPHY; FEMALE; HUMANS; HYPERTENSION, PULMONARY; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS; SCLERODERMA, SYSTEMIC;

EID: 46949105586     PISSN: 03009742     EISSN: 15027732     Source Type: Journal    
DOI: 10.1080/03009740801978871     Document Type: Article

References (42)

1. Williams MH, Das C, Handler CE, Akram MR, Davar J, Denton CP, et al. Systemic sclerosis associated pulmonary hypertension: improved survival in the current era. Heart 2006;92:926-32.
2. Girgis RE, Mathai SC, Krishnan JA, Wigley FM, Hassoun PM. Long-term outcome of bosentan treatment in idiopathic pulmonary arterial hypertension and pulmonary arterial hypertension associated with the scleroderma spectrum of diseases. J Heart Lung Transplant 2005;24:1626-31.
3. Denton CP, Humbert M, Rubin L, Black CM. Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions. Ann Rheum Dis 2006;65:1336-40.
4. de Azevedo AB, Sampaio-Barros PD, Torres RM, Moreira C. Prevalence of pulmonary hypertension in systemic sclerosis. Clin Exp Rheumatol 2005;23:447-54.
5. Koh ET, Lee P, Gladman DD, bu-Shakra M. Pulmonary hypertension in systemic sclerosis: an analysis of 17 patients. Br J Rheumatol 1996;35:989-93.
6. McLaughlin VV. Survival in patients with pulmonary arterial hypertension treated with first-line bosentan. Eur J Clin Invest 2006;36(Suppl 3):10-15.
7. Chang B, Wigley FM, White B, Wise RA. Scleroderma patients with combined pulmonary hypertension and interstitial lung disease. J Rheumatol 2003;30:2398-405.
8. Schachna L, Wigley FM, Chang B, White B, Wise RA, Gelber AC. Age and risk of pulmonary arterial hypertension in scleroderma. Chest 2003;124:2098-104.
9. Steen V, Medsger TA Jr. Predictors of isolated pulmonary hypertension in patients with systemic sclerosis and limited cutaneous involvement. Arthritis Rheum 2003;48:516-22.
10. Steen V. Predictors of end stage lung disease in systemic sclerosis. Ann Rheum Dis 2003;62:97-9.
11. Hesselstrand R, Ekman R, Eskilsson J, Isaksson A, Scheja A, Ohlin AK, et al. Screening for pulmonary hypertension in systemic sclerosis: the longitudinal development of tricuspid gradient in 227 consecutive patients, 1992-2001. Rheumatology (Oxford) 2005;44:366-71.
12. Mukerjee D, St George D, Knight C, Davar J, Wells AU, Du Bois RM, et al. Echocardiography and pulmonary function as screening tests for pulmonary arterial hypertension in systemic sclerosis. Rheumatology (Oxford) 2004;43:461-6.
13. Trad S, Amoura Z, Beigelman C, Haroche J, Costedoat N, Boutin LT, et al. Pulmonary arterial hypertension is a major mortality factor in diffuse systemic sclerosis, independent of interstitial lung disease. Arthritis Rheum 2006;54:184-91.
14. Stupi AM, Steen VD, Owens GR, Barnes EL, Rodnan GP, Medsger TA Jr. Pulmonary hypertension in the CREST syndrome variant of systemic sclerosis. Arthritis Rheum 1986;29:515-24.
15. Plastiras SC, Karadimitrakis SP, Kampolis C, Moutsopoulos HM, Tzelepis GE. Determinants of pulmonary arterial hypertension in scleroderma. Semin Arthritis Rheum 2007;36:392-6.
16. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum 1980;23:581-90.
17. Alarcon-Segovia D, Cardiel MH. Comparison between 3 diagnostic criteria for mixed connective tissue disease. Study of 593 patients. J Rheumatol 1989;16:328-34.
18. LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA Jr, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988;15:202-5.
19. Schurawitzki H, Stiglbauer R, Graninger W, Herold C, Polzleitner D, Burghuber OC, et al. Interstitial lung disease in progressive systemic sclerosis: high-resolution CT versus radiography. Radiology 1990;176:755-9.
20. Fujita J, Yoshinouchi T, Ohtsuki Y, Tokuda M, Yang Y, Yamadori I, et al. Non-specific interstitial pneumonia as pulmonary involvement of systemic sclerosis. Ann Rheum Dis 2001;60:281-3.
21. Plastiras SC, Karadimitrakis SP, Ziakas PD, Vlachoyiannopoulos PG, Moutsopoulos HM, Tzelepis GE. Scleroderma lung: initial forced vital capacity as predictor of pulmonary function decline. Arthritis Rheum 2006;55:598-602.
22. Afeltra A, Zennaro D, Garzia P, Gigante A, Vadacca M, Ruggiero A, et al. Prevalence of interstitial lung involvement in patients with connective tissue diseases assessed with high-resolution computed tomography. Scand J Rheumatol 2006;35:388-94.
23. Nishimura RA, Miller FA Jr, Callahan MJ, Benassi RC, Seward JB, Tajik AJ. Doppler echocardiography: theory, instrumentation, technique, and application. Mayo Clin Proc 1985;60:321-43.
24. Simonson JS, Schiller NB. Sonospirometry: a new method for noninvasive estimation of mean right atrial pressure based on two-dimensional echographic measurements of the inferior vena cava during measured inspiration. J Am Coll Cardiol 1988;11:557-64.
25. Murata I, Takenaka K, Yoshinoya S, Kikuchi K, Kiuchi T, Tanigawa T, et al. Clinical evaluation of pulmonary hypertension in systemic sclerosis and related disorders. A Doppler echocardiographic study of 135 Japanese patients. Chest 1997;111:36-43.
26. McQuillan BM, Picard MH, Leavitt M, Weyman AE. Clinical correlates and reference intervals for pulmonary artery systolic pressure among echocardiographically normal subjects. Circulation 2001;104:2797-802.
27. MacGregor AJ, Canavan R, Knight C, Denton CP, Davar J, Coghlan J, et al. Pulmonary hypertension in systemic sclerosis: risk factors for progression and consequences for survival. Rheumatology (Oxford) 2001;40:453-9.
28. Hachulla E, Gressin V, Guillevin L, Carpentier P, Diot E, Sibilia J, et al. Early detection of pulmonary arterial hypertension in systemic sclerosis: a French nationwide prospective multicenter study. Arthritis Rheum 2005;52:3792-800.
29. Steen V. Advancements in diagnosis of pulmonary arterial hypertension in scleroderma. Arthritis Rheum 2005;52:3698-700.
30. Hesselstrand R, Scheja A, Shen GQ, Wiik A, Akesson A. The association of antinuclear antibodies with organ involvement and survival in systemic sclerosis. Rheumatology (Oxford) 2003;42:534-40.
31. Steen VD. Autoantibodies in systemic sclerosis. Semin Arthritis Rheum 2005;35:35-42.
32. Alkotob ML, Soltani P, Sheatt MA, Katsetos MC, Rothfield N, Hager WD, et al. Reduced exercise capacity and stress-induced pulmonary hypertension in patients with scleroderma. Chest 2006;130:176-81.
33. Steen VD, Ziegler GL, Rodnan GP, Medsger TA Jr. Clinical and laboratory associations of anticentromere antibody in patients with progressive systemic sclerosis. Arthritis Rheum 1984;27:125-31.
34. Kyndt X, Launay D, Hebbar M, Hatron PY, Fournier C, Michon-Pasturel U, et al. Influence of age on the clinical and biological characteristics of systemic scleroderma. Rev Med Interne 1999;20:1088-92.
35. Beretta L, Caronni M, Origgi L, Ponti A, Santaniello A, Scorza R. Hormone replacement therapy may prevent the development of isolated pulmonary hypertension in patients with systemic sclerosis and limited cutaneous involvement. Scand J Rheumatol 2006;35:468-71.
36. Scorza R, Caronni M, Bazzi S, Nador F, Beretta L, Antonioli R, et al. Post-menopause is the main risk factor for developing isolated pulmonary hypertension in systemic sclerosis. Ann N Y Acad Sci 2002;966:238-46.
37. Chang B, Schachna L, White B, Wigley FM, Wise RA. Natural history of mild-moderate pulmonary hypertension and the risk factors for severe pulmonary hypertension in scleroderma. J Rheumatol 2006;33:269-74.
38. McGoon M, Gutterman D, Steen V, Barst R, McCrory DC, Fortin TA, et al. Screening, early detection, and diagnosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest 2004;126:14S-34S.
39. Distler O, Pignone A. Pulmonary arterial hypertension and rheumatic diseases - from diagnosis to treatment. Rheumatology (Oxford) 2006;45(Suppl 4):iv22-5.
40. Plastiras SC, Kelekis N, Tzelepis GE. Magnetic resonance imaging for the detection of myocardial fibrosis in scleroderma. N Engl J Med 2006;354:2194-6.
41. Tzelepis GE, Kelekis NL, Plastiras SC, Mitseas P, Economopoulos N, Kampolis C, et al. Pattern and distribution of myocardial fibrosis in systemic sclerosis: a delayed enhanced magnetic resonance imaging study. Arthritis Rheum 2007;56:3827-36.
42. Kahan A, Allanore Y. Primary myocardial involvement in systemic sclerosis. Rheumatology (Oxford) 2006;45(Suppl 4):iv14-17.